Drug Database
OM

omeprazole (Omez Insta)

✓ Approved

Dr.Reddy's Laboratories Ltd. · ATP4A · Small Molecule

What is omeprazole?

omeprazole is a small molecule developed by Dr.Reddy's Laboratories Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOmez Insta
CompanyDr.Reddy's Laboratories Ltd.
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Dr.Reddy's Laboratories Ltd.

Mechanism of Action

Molecular Targets

omeprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

omeprazole is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersGastritis✓ Approved

Related Research Articles

PubMedSaudi medical journal2026-09-19

Potential Drug-Drug Interactions in Patients Undergoing Hemodialysis: A Retrospective Observational Study.

Al-Ammash Buthainah B BB, Alharbi Fawaz A FA, Al-Hejaili Omar D OD, Mahmoud Mansour A MA et al.

To evaluate the prevalence, characteristics, and determinants of potential drug-drug interactions (pDDIs) among patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) at a tertiary care hospital in Al-Madinah Al-Monawara, Kingdom of Saudi Arabia. Data for this retrospective observational study were extracted from the electronic medical records of adult patients (≥ 18 years) diagnosed with ESRD and receiving hemodialysis (HD) between October 2022 and March 2023. The pDDIs were identified and classified using Lexicomp® (Wolters Kluwer, Alphen aan den Rijn, Netherlands). Descriptive statistics summarized patient characteristics and pDDIs, and univariate logistic regression was implemented to investigate the determinants associated with the occurrence of pDDI. Among 287 patients, 264 (92%) experienced at least 1 pDDI. In total, 4,157 pDDIs were identified, most of which were Category C (75.4%), followed by Categories B and D. Category X interactions were uncommon (n = 78), with clopidogrel-omeprazole and clopidogrel-esomeprazole being the most frequent. Patients received a mean of 14 ± 5.1 medications. Logistic regression showed that the number of prescribed medications was significantly associated with pDDI occurrence (odds ratio = 2.03; p = 0.001). The pDDIs are highly prevalent among patients with ESRD undergoing HD, with polypharmacy identified as the main determinant. These findings highlight the importance of structured medication review, multidisciplinary collaboration, and clinical pharmacist involvement to reduce medication-related risks and optimize patient outcomes.

PMID 42761988
Read full article →
PubMedInternational journal of pharmaceutical compounding2026-09-17

Stability Evaluation of Compounded Multidrug Oral Liquids in a Dual-Vehicle Suspending System.

Kegele Carolina Schettino CS, Taylor Sarah S, Polonini Hudson H

Extemporaneously compounded oral liquids are essential for patients unable to swallow solid dosage forms, although ensuring stability in aqueous systems remains challenging. This study evaluated the chemical, physical, and microbiological stability of formulations containing topiramate, omeprazole, gabapentin, ondansetron, and levofloxacin prepared in Flavor Sweet™ SF and Flavor Plus™, also known as Syra Sweet™ SF and Syra Plus™. Stability was assessed over 90 days at room temperature and under refrigeration using validated UHPLC methods, along with physical and microbiological analyses. Gabapentin, ondansetron, omeprazole, and topiramate remained stable for 90 days under both conditions, while levofloxacin was stable for 60 days at room temperature and 90 days refrigerated. All formulations showed consistent pH and acceptable microbiological quality, although precipitation in some samples led to discontinuation of analysis. These results support the suitability of the vehicle system and highlight the importance of formulation parameters in stability and beyond-use dating.

PMID 42752430
Read full article →
PubMedMedicine2026-09-15

Cost-effectiveness analysis of omeprazole for preventing esophageal stricture in patients with Zargar grade 2b and 3a corrosive esophageal injuries: A trial-based economic evaluation.

Mahawongkajit Prasit P, Orrapin Saritphat S, Tomtitchong Prakitpunthu P, Havanond Chittinad C

Corrosive esophageal injury frequently results in esophageal stricture requiring repeated endoscopic dilatation and substantial healthcare expenditure. This study evaluated the cost-effectiveness of omeprazole plus standard treatment compared with standard treatment alone for preventing esophageal stricture in adult patients with Zargar grade 2b and 3a corrosive esophageal injuries. A trial-based economic evaluation was conducted alongside a randomized controlled trial from the healthcare provider and patient perspectives. Twenty patients were randomized to receive either standard treatment alone (n = 10) or standard treatment plus omeprazole (n = 10). Direct medical costs were analyzed using the incremental cost-effectiveness ratio. Deterministic one-way sensitivity analysis and probabilistic sensitivity analysis using Monte Carlo simulation were performed. The incidence of corrosive esophageal stricture was 20% (2/10) in the omeprazole group and 70% (7/10) in the standard treatment group (relative risk, 0.29; 95% confidence interval, 0.08-1.05; Fisher's exact test, P = .070). Omeprazole plus standard treatment reduced healthcare costs by THB 4642.30 per patient from the provider perspective and THB 5476.60 per patient from the patient perspective. The intervention remained the dominant strategy across all deterministic sensitivity analyses. Probabilistic sensitivity analysis demonstrated that 68.3% and 78.8% of simulations favored omeprazole from the provider and patient perspectives, respectively. Omeprazole plus standard treatment may represent a cost-effective strategy for adult patients with Zargar grade 2b and 3a corrosive esophageal injuries. However, these findings should be considered preliminary and require confirmation in larger multicenter randomized controlled trials.

PMID 42736784
Read full article →
PubMedChemistry & biodiversity2026-09-15

Computational, In Vitro, and In Vivo Evaluation of Benzimidazole-Pyrazole Hybrid Scaffolds as Multi-Target Anti-Ulcer Agents.

Kharl Hafiz Aamir Ali HAA, Malik Abdul A, Nadeem Humaira H, Ola Mohammad Shamsul MS et al.

Peptic ulcer disease (PUD) continues to be an important gastrointestinal condition attributed to Helicobacter pylori infection, usage of nonsteroidal anti-inflammatory drugs, oxidative stress, and inflammatory mediators. Although there are available treatments for this condition, side effects, relapse, and safety issues call for development of new multi-target anti-ulcer compounds. In this research, a group of benzimidazole-pyrazole analogs (5a-5j) was designed, synthesized, and studied with the aid of computational and experimental methods. Molecular docking into H+/K+-ATPase (PDB ID: 5YLU) and COX-2 (PDB ID: 3LN1) enzymes predicted high affinity of these compounds with docking scores of -9.4 and -9.3 kcal/mol for compounds 5i and 5e, respectively, higher than those obtained for the reference drugs omeprazole and celecoxib. The inhibition of the gastric H+/K+-ATPase enzyme was also observed in vitro, with compounds 5i and 5e having better inhibitory effects. Studies on the ethanol and indomethacin-induced gastric ulceration models demonstrated good inhibitory effects of these compounds. Biochemical analysis showed that these analogs significantly decreased the levels of TNF-α, COX-2, myeloperoxidase, and malondialdehyde and increased prostaglandin E2. Acute oral toxicity studies indicated no observable toxicity at 100 mg/kg. Collectively, these findings identify compounds 5i and 5e as promising multifunctional gastroprotective candidates warranting further pharmacological investigation.

PMID 42742036
Read full article →
PubMedAAPS PharmSciTech2026-09-15

Rutin loaded nanosponges for treatment of peptic ulcer: in silico, pharmacodynamic and pharmacokinetic studies.

Rao Monica Rp MR, Bagwan Bushra Ashpak BA

Peptic ulcer disease (PUD) is a multifactorial condition influenced by oxidative stress, Helicobacter pylori infection and excessive gastric acid secretion. Rutin (RTN), a plant-derived flavonoid with antioxidant, anti-inflammatory and proton pump inhibition properties, offers therapeutic promise but suffers from poor aqueous solubility and low bioavailability. To overcome these limitations, RTN-loaded β-cyclodextrin-based nanosponges (RTN-NS₄) were developed and extensively characterized. Phase solubility studies revealed AL type of curve. DSC and PXRD indicated enhanced amorphization while FTIR confirmed successful drug encapsulation. SEM imaging revealed flaky, nanoscale morphology. RTN-NS₄ exhibited a 25.4-fold increase in saturation solubility compared to RTN. Antioxidant potential, assessed by DPPH assay, showed significantly higher antioxidant activity for RTN-NS₄ of 87.91% at 500 μg/ml, indicating enhanced ROS-scavenging ability. Molecular docking studies further confirmed RTN's strong binding affinity towards H+/K+-ATPase (glide energy of -62.822 kcal/mol) showing enhanced binding affinity and complex stability. In comparison, vonoprazon showed glide energy of -58.450 kcal/mol. These studies also confirmed that RTN has greater binding with NS (glide energy:-37.924 kcal/mol) than β-CD (glide energy:-33.034 kcal/mol). RTN-NS₄ achieved 42 ± 7.23% ulcer inhibition in ethanol-induced gastric ulcers in Wistar rats, surpassing RTN (22.17 ± 6.53%) but 18% lower than omeprazole (60.16 ± 8.23%). Histological studies confirmed moderate mucosal protection and reduced inflammation in RTN-NS₄-treated rats. These results underscore RTN-NS₄ as promising nanophyto-therapeutic system offering synergistic antioxidant, anti-inflammatory and PPI activity effects for effective ulcer management without the concomitant side effects of PPIs.

PMID 42736524
Read full article →
PubMedBritish journal of clinical pharmacology2026-09-15

Prevalence of pharmacogenomically implicated prescriptions in multi-ethnic populations in Singapore.

Loo Zavier Zhe Xuan ZZX, Li Zhenhua Z, Lee Sean Zhuo Xuan SZX, Sin Min Thant MT et al.

To assess the potential impact of implementing pre-emptive pharmacogenomic (PGx) testing in Singapore, focusing on prevalence and genetic actionability of PGx prescriptions. Electronic Health Records from 2014 to 2021 were obtained from the National University Hospital (NUH), a tertiary medical centre serving approximately 6% of Singapore's population, which were filtered for pharmacogenomically implicated medicines (CPIC Level A or A/B), defined as PGx medications. Coupling this with published data of whole-genome sequencing of 9051 Singaporeans, we estimated the proportion of patients whose prescriptions might have been modified based on pre-emptive PGx at population level. From 2014 to 2021, a total of 1 157 359 unique patients were seen at NUH, with 38.1% to 43.0% of patients with prescriptions receiving at least one PGx medication annually, exhibiting minimal variance over year of prescription, sex or race/ethnicity. The most frequently prescribed PGx medications were omeprazole, statins and tramadol, while the most implicated pharmacogenes were CYP2C19, CYP2D6 and SLCO1B1. The age-dependent increase in PGx medication exposure varied significantly by sex, with males prescribed these medications earlier in life than females. Similarly, Indians and Malays were more likely to be prescribed these medicines at a younger age than Chinese. Based on frequency of PGx variants in Singaporeans, we estimate that 18.4% of patients could have their prescriptions modified from pre-emptive PGx testing. Pharmacogenomically implicated medication prescriptions are common in Singapore and are particularly prevalent in elderly populations. Strategic investments in infrastructure and policy development will be pivotal to the successful integration of pre-emptive PGx into clinical practice.

PMID 42740528
Read full article →

+9709 more articles available with a free account

Sign up free to view all articles →

Ask about omeprazole